AndreaBozzo/ceres-open-data-index huggingface dataset:
Detroit: Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in the Detroit metropolitan area, covering 2004-2011.  Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.
Compound 528918: Thiophene, 3-(2-methylpropyl)thio

Chemical compound data from PubChem database. IUPAC Name: 3-(2-methylpropylsulfanyl)thiophene. Molecular Formula: C8H12S2. Molecular Weight: 172.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA DataNational Directory of Drug and Alcohol Abuse Treatment Facilities - 2020

The National Directory of Drug and Alcohol Abuse Treatment Facilities - 2020 is a listing of federal, state, and local government facilities and private facilities that provide substance abuse treatment services. It includes treatment facilities that (1) are licensed, certified, or otherwise approved for inclusion in the Directory by their State Substance Abuse Agencies, and (2) responded to the 2019 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this Directory was provided by that facility in response to the 2019 N-SSATS. N-SSATS is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA).The Directory is ordered alphabetically by state, by city within each state, and by facility name within each city. Each facility listing includes codes that represent the services offered and other features of the facility, including codes that indicate services for hearing impaired and non-English-speaking clients. Codes are defined in a key shown on pages v-x. Because the services offered by a particular facility may change over time, it is always a good idea to verify the information in this Directory when contacting a facility.
Compound 526945: 3-Ethyl-1,2-dithiolan-4-one

Chemical compound data from PubChem database. IUPAC Name: 3-ethyldithiolan-4-one. Molecular Formula: C5H8OS2. Molecular Weight: 148.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Long-Term Care Calculator: Compare Costs, Types of Service in Your Area

<p>This report estimates the economic value of family caregiving at $450 billion in 2009 based on 42.1 million caregivers age 18 or older providing an average of 18.4 hours of care per week to care recipients age 18 or older, at an average value of $11.16 per hour.</p>
<p><strong><em>This data is not collected by a government agency.  The findings and conclusions in this report are those of the author and do not necessarily represent the views of the Department of Health &amp; Human Services.</em></strong></p>
Compound 527113: 6,9-Guaiadiene

Chemical compound data from PubChem database. IUPAC Name: 1,4-dimethyl-7-propan-2-yl-1,2,3,4,5,8-hexahydroazulene. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011-2012 NSDUH National Maps of Prevalence Estimates by State

2011-2012 NSDUH National Maps of Prevalence Estimates by State. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 527594: 3-Buten-1-ol, tribromoacetate

Chemical compound data from PubChem database. IUPAC Name: but-3-enyl 2,2,2-tribromoacetate. Molecular Formula: C6H7Br3O2. Molecular Weight: 350.83. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401797-T1: [Translated] ADDITIVE COMPOSITION CONTAINING INORGANIC PARTICLES, METHOD FOR THE PRODUCTION THEREOF AND FOOD PRODUCT CONTAINING THE ADDITIVE COMPOSITION

An inorganic particles-containing additive composition is disclosed which contains a polyvalent metal, a phosphoric acid ion, an organic acid having a carboxyl group and an alkali metal, said composition satisfying the following requirements of (a) and (b): <DF>(a) 70 </= X </= 90000 </DF> X: Amount (mg/Kg) of the alkali metal contained in a solid content of the additive composition, <DF>(b) 0.1 </= Y </= 15 </DF> Y: Electric conductivity (mS/cm) when the additive composition is adjusted to a solid concentration of 10 % by weight. <??>The additive composition is excellent not only in dispersibility and storage stability in a liquid, but also in flavor.
Hospital Inpatient Discharges (SPARCS De-Identified): 2013

The Statewide Planning and Research Cooperative System (SPARCS) Inpatient De-identified File contains discharge level detail on patient characteristics, diagnoses, treatments, services, and charges.  This data file contains basic record level detail for the discharge.  The de-identified data file does not contain data that is protected health information (PHI) under HIPAA.  The health information is not individually identifiable; all data elements considered identifiable have been redacted.  For example, the direct identifiers regarding a date have the day and month portion of the date removed.
Joint Letter to Family Support, Maternal and Child Health, and Early Childhood Programs on Strategies During COVID-19 Pandemic

This letter, which was jointly issued by the Administration for Children and Families and the Health Resources and Services Administration of the U.S. Department of Health and Human Services, encourages family support, maternal and child health, and early childhood programs to promote family strengthening and prevention strategies via virtual, electronic, telephonic, or other safe means during the COVID-19 pandemic.

Browse All COVID-19 Resources

Metadata-only record linking to the original dataset. Open original dataset below.
Blog | COVID-19 is Complex, as is COVID-19 Open Data

This blog post was posted by Kevin Duvall on December 7, 2020. It was written by By: Kristen Honey, Chief Data Scientist and Senior Advisor to Assistant Secretary for Health (ASH), HHS; Amy Gleason, Data Strategy and Execution Workgroup Lead, U.S. Digital Service; and Kevin Duvall, Deputy Chief Data Officer (CDO), Office of the CDO, HHS.
Compound 526603: 5-O-Acetyl-2,6-anhydro-1,3,4-tri-O-methylhexitol

Chemical compound data from PubChem database. IUPAC Name: [4,5-dimethoxy-6-(methoxymethyl)oxan-3-yl] acetate. Molecular Formula: C11H20O6. Molecular Weight: 248.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Assessment of the infectious diseases surveillance system of the Republic of Armenia: an example of surveillance in the Republics of the former Soviet Union

Background
          Before 1991, the infectious diseases surveillance systems (IDSS) of the former Soviet Union (FSU) were centrally planned in Moscow. The dissolution of the FSU resulted in economic stresses on public health infrastructure. At the request of seven FSU Ministries of Health, we performed assessments of the IDSS designed to guide reform. The assessment of the Armenian infectious diseases surveillance system (AIDSS) is presented here as a prototype.
        
        
          Discussion
          We performed qualitative assessments using the Centers for Disease Control and Prevention (CDC) guidelines for evaluating surveillance systems. Until 1996, the AIDSS collected aggregate and case-based data on 64 infectious diseases. It collected information on diseases of low pathogenicity (e.g., pediculosis) and those with no public health intervention (e.g., infectious mononucleosis). The specificity was poor because of the lack of case definitions. Most cases were investigated using a lengthy, non-disease-specific case-report form Armenian public health officials analyzed data descriptively and reported data upward from the local to national level, with little feedback. Information was not shared across vertical programs. Reform should focus on enhancing usefulness, efficiency, and effectiveness by reducing the quantity of data collected and revising reporting procedures and information types; improving the quality, analyses, and use of data at different levels; reducing system operations costs; and improving communications to reporting sources. These recommendations are generalizable to other FSU republics.
        
        
          Summary
          The AIDSS was complex and sensitive, yet costly and inefficient. The flexibility, representativeness, and timeliness were good because of a comprehensive health-care system and compulsory reporting. Some data were questionable and some had no utility.
Funding Opportunity Announcement for Tribal Title IV-E Plan Development Grants

The Children’s Bureau (CB), within the Administration for Children and Families (ACF), held two Tribal consultation calls to discuss a forthcoming funding opportunity announcement (FOA). CB is seeking input from Tribal leaders to ensure these opportunities are designed in a well-informed and culturally responsive way to best position for success.

The Standing Announcement for Tribal Title IV-E Plan Development Grants
  
  

 (HHS-2016-ACF-ACYF-CS-1176)

The purpose of the FOA is to solicit proposals for one-time grants to Tribes, Tribal organizations, or Tribal consortia that are seeking to develop and, within 24 months of grant receipt, submit to the Department of Health and Human Services a plan to implement a title IV-E foster care, adoption assistance, and, at Tribal option, guardianship assistance program. Grant funds under this FOA may be used for the cost of developing a title IV-E plan under section 471 of the Social Security Act (the Act) to carry out a program under section 479B of the Act. The grant may be used for costs relating to the development of case planning and case review systems, foster care licensing and standards for Tribal foster homes and child care facilities, quality assurance systems, court structure and procedures, data collection systems, cost allocation methodology development, financial controls and financial management processes, or any other costs attributable to meeting any other requirement necessary for approval of a title IV-E plan.

Please submit all written comments to the Children’s Bureau at TribalFOA@acf.hhs.gov. We’ve been experiencing some problems with that email address, so please copy your written comments to Eileen West’s email address: eileen.west@acf.hhs.gov.

CB held Tribal consultation calls to discuss this funding opportunity on two dates, Tuesday, March 8, 2016 and Thursday, March 10, 2016. Both calls were held at 2:00 pm Eastern Standard Time and were recorded. The audio and transcript files are available for download below.

Metadata-only record linking to the original dataset. Open original dataset below.
The intronic G13964C variant in

Background
          Mutations in BRCA1 and BRCA2 account for approximately 50% of breast cancer families with more than four affected cases, whereas exonic mutations in p53, PTEN, CHK2 and ATM may account for a very small proportion. It was recently reported that an intronic variant of p53 - G13964C - occurred in three out of 42 (7.1%) 'hereditary' breast cancer patients, but not in any of 171 'sporadic' breast cancer control individuals (P = 0.0003). If this relatively frequent occurrence of G13964C in familial breast cancer and absence in control individuals were confirmed, then this would suggest that the G13964C variant plays a role in breast cancer susceptibility.
        
        
          Method
          We genotyped 71 familial breast cancer patients and 143 control individuals for the G13964C variant using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis.
        
        
          Results
          Three (4.2%; 95% confidence interval [CI] 0–8.9%) G13964C heterozygotes were identified. The variant was also identified in 5 out of 143 (3.5%; 95% CI 0.6–6.4%) control individuals without breast cancer or a family history of breast cancer, however, which is no different to the proportion found in familial cases (P = 0.9).
        
        
          Conclusion
          The present study would have had 80% power to detect an odds ratio of 4.4, and we therefore conclude that the G13946C polymorphism is not a 'high-risk' mutation for familial breast cancer.
Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health

This national report summarizes key findings from the 2016 National Survey on Drug Use and Health (NSDUH) for indicators of substance use and mental health among people aged 12 years old or older in the civilian, noninstitutionalized population of the United States.  Estimates include tobacco use, alcohol use, illicit drug use, opioid use, substance use disorders, major depressive episode, any mental illness, serious mental illness, suicide, co-occurring disorders, and receipt of treatment or services.
Compound 526378: 1,2-Dibromo,4,9-dichloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2-dibromo-4,9-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 20. Illicit Drug Dependence in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs

Table 20. Illicit Drug Dependence in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs
Genetics of rheumatoid arthritis: confronting complexity

The genetic basis for rheumatoid arthritis (RA) is likely to be			 extremely complex. Even the role of MHC genes remains to be fully defined, and			 may involve interactive genetic effects. The difficulty of precisely defining			 the clinical phenotype, as well as underlying genetic heterogeneity,			 complicates the problem. In addition, stochastic genetic or physiologic events			 may contribute to the low penetrance of susceptibility genes. This situation			 parallels developing paradigms for other autoimmune disorders, in which many			 different genes each appear to contribute a small amount to overall risk for			 disease, and where severity and specific phenotypic subtypes are subject to			 genetic effects. The completion of the human genome project, along with			 advances in informatics, will be required to reach a deeper understanding of			 RA. It is likely that this will involve an iterative and interactive process			 between several different scientific disciplines.
Confounding factors in diagnosing brain death: a case report

Background
          Brain death is strictly defined medically and legally. This diagnosis depends on three cardinal neurological features: coma, absent brainstem reflexes, and apnea. The diagnosis can only be made, however, in the absence of intoxication, hypothermia, or certain medical illnesses.
        
        
          Case presentation
          A patient with severe hypoxic-ischemic brain injury met the three cardinal neurological features of brain death but concurrent profound hypothyroidism precluded the diagnosis. Our clinical and ethical decisions were further challenged by another facet of this complex case. Although her brain damage indicated a hopeless prognosis, we could not discontinue care based on futility because the only known surrogate was mentally retarded and unable to participate in medical planning.
        
        
          Conclusion
          The presence of certain medical conditions prohibits a diagnosis of brain death, which is a medicolegal diagnosis of death, not a prediction or forecast of future outcome. While prognostication is important in deciding to withdraw care, it is not a component in diagnosing brain death.
Patent AT-E399906-T1: [Translated] CONSTRUCTION KIT FOR AN ENERGY SAVING HOUSE

The assembly kit for an energy saving house with an insulation-glazed winter garden (1) and a house unit (2). The enclosed volume of the winter garden exceeds that of the house unit by a multiple, and the winter garden encompasses the house unit on all sides in the form of a weather enclosure. The house unit is located off-center inside the winter garden, and the winter garden has openings for the leading through of service ducts such as a chimney or a ventilation shaft.
Jejunogastric intussusception presented with hematemesis: a case presentation and review of the literature

Background
          Jejunogastric intussusception (JGI) is a rare but potentially very serious complication of gastrectomy or gastrojejunostomy. To avoid mortality early diagnosis and prompt surgical intervention is mandatory.
        
        
          Case presentation
          A young man presented with epigastric pain and bilous vomiting followed by hematemesis,10 years after vagotomy and gastrojejunostomy for a bleeding duodenal ulcer. Emergency endoscopy showed JGI and the CT scan of the abdomen was compatible with this diagnosis. At laparotomy a retrograde type II, JGI was confirmed and managed by reduction of JGI without intestinal resection. Postoperative recovery was uneventful.
        
        
          Conclusions
          JGI is a rare condition and less than 200 cases have been published since its first description in 1914. The clinical picture is almost diagnostic. Endoscopy performed by someone familiar with this rare entity is certainly diagnostic and CT-Scan of the abdomen could also help. There is no medical treatment for acute JGI and the correct treatment is surgical intervention as soon as possible.
Compound 526862: Pentaethylene glycol, pentyl ether, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-[2-[2-[2-(2-pentoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]silane. Molecular Formula: C18H40O6Si. Molecular Weight: 380.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Plan Attributes PUF - PY2016

The Plan Attributes PUF (Plan-PUF) is one of the seven files that make up the Marketplace PUF. The Plan-PUF contains plan-level data on maximum out of pocket payments, deductibles, cost sharing, health savings account (HSA) eligibility, formulary ID, and other plan attributes. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated). The issuer can also import data created in other templates (e.g., Network IDs from the Network ID template, Service Area IDs from the Service Area template, and Formulary IDs from the Prescription Drug template) to use as allowable values for the applicable fields in the Plans &amp; Benefits template, or enter these values manually.
19th NCCAN Day Three Closing Plenary

The 19th National Conference on Child Abuse and Neglect (NCCAN) was held from April 30 to May 2, 2014, in New Orleans, LA. Each day featured a plenary session on a specific topic. The day three closing plenary included a presentation by Joy P. Osofsky, Ph.D., and D.J. Markey titled "Lessons for Connectors on Overcoming Trauma and Building Resilience." Desmond Runyan, M.D., Dr.P.H., presented the Kempe Scientific Impact Award to David Finkelhor, Ph.D. David P. Kelly, Child Welfare Program Specialist for Court Improvement, Children’s Bureau, and Melissa Lim Brodowski, Ph.D., M.S.W., M.P.H., also spoke.

Metadata-only record linking to the original dataset. Open original dataset below.
Los Angeles Times Poll, 1985

This opinion study was designed to determine the prevalence of childhood sexual abuse among a national sample of adult men and women and to identify characteristics of victims and risk factors associated with childhood sexual victimization. The sampling frame included all residential telephones in the United States.  2,629 men and women 18 years or older were contacted by telephone during an eight day period in July of 1985.  Knowledge and attitudes about sexual abuse were ascertained and information was gathered about the respondents' personal life circumstances.

Investigators: Lewis, I.A.
Compound 525722: (p-Methylbenzylidene)-benzyl-amine

Chemical compound data from PubChem database. IUPAC Name: N-benzyl-1-(4-methylphenyl)methanimine. Molecular Formula: C15H15N. Molecular Weight: 209.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
South Dakota: 2011-2012 NSDUH

This report presents South Dakota\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Rational therapy of chronic venous insufficiency – chances and limits of the therapeutic use of horse-chestnut seeds extract

Background and methods
          We report two clinical studies, one already published, performed in patients with early and advanced chronic venous insufficiency (CVI). In both, compression therapy and oral therapy with horse-chestnut seeds extracts (HCSE) were compared to placebo.
        
        
          Results
          The published study in early CVI (Grade I) showed HCSE and compression to be superior to placebo and to be equivalent to each other in reducing lower leg volume, a measure for oedema.
          In the study, in advanced CVI (Grade II and IIIa), compression appeared to be superior to placebo, whereas HCSE was not. HCSE fared better in Grade II than in Grade IIIa patients.
          These results are discussed in the light of data from an in vitro model, where HCSE has been able to close the intercellular gaps in the venular endothelium. Not fully specified factors lead to an opening of these gaps, resulting in oedema as well as in local coagulation and thrombosis. The subsequent inflammation keeps these gaps open and initiates and maintains a chronic disease process, which may be the starting point of CVI.
        
        
          Conclusion
          Due to its ability to close the venular endothelial gaps, HCSE seems to be a suitable and protecting therapy during the early stages of CVI. In later more severe stages compression therapy is indicated. Taking into account the observed negative impact of compression on quality of life, pharmacological CVI therapy should start early to avoid progress and to spare patients compression therapy.